NextCure (NXTC) Q2 2026 earnings summary

Executive summary

• Entered into a definitive all-stock merger agreement with Avere Therapeutics on July 14, 2026, with the combined company to operate as Avere Therapeutics, Inc. under the ticker AVRX, pending stockholder approval and closing conditions.

• Announced concurrent private financing of approximately $320 million in gross proceeds expected upon merger closing.

• Initiated major restructuring, including substantial workforce reduction, facility reductions, and asset sales to align with the combined company's strategy and preserve capital.

• Entered Transition and Continuation Agreement with LigaChem for LNCB74, transferring full responsibility and eligibility for future milestone and royalty payments.

• Existing shareholders to receive contingent value rights (CVRs) tied to legacy assets.

Financial highlights

• Net loss for Q2 2026 was $14.9 million, compared to $26.8 million or $28.0 million in Q2 2025; net loss for the first half of 2026 was $24.7 million, down from $37.8 million in the prior year period.

• Research and development expenses decreased to $7.4 million in Q2 2026 from $24.1 million in Q2 2025, mainly due to a prior year $17 million license fee and lower internal costs.

• General and administrative expenses fell to $2.6 million in Q2 2026 from $3.2 million in Q2 2025, mainly due to lower personnel costs.

• Recorded $5.1 million in asset impairment charges in Q2 2026 related to restructuring and asset disposals.

• Cash, cash equivalents, and marketable securities totaled $20.1 million as of June 30, 2026, down from $41.8 million at December 31, 2025.

Outlook and guidance

• Cash runway expected to last into Q4 2026; future liquidity and capital requirements depend on the completion of the merger and related financing.

• If the merger is not completed, additional funding or strategic alternatives will be required, with potential for further cost reductions or dissolution.

• The merger is expected to close in the second half of 2026, subject to stockholder approval and customary conditions.

• Focus remains on preserving capital, supporting ongoing clinical programs, and maximizing value from legacy assets.

• Restructuring and severance costs of approximately $2.4 million expected, primarily in Q3 2026.